A long-term production and technology transfer agreement with Brazil was signed, reinforcing CHIL’s commitment to sustainable global manufacturing partnerships.

CHIL initiated patent applications and product development efforts focused on the detection of breast cancer and breast anomalies, signaling a…

In April 2023, Dr. Ourania conducted a CORONOMICS interview with Founder Hilda Cil, focusing on the global pandemic and its…

On 19 July 2022, CHIL signed a university industry cooperation protocol with Bakırçay University to jointly conduct R&D activities and…

Driven by global demand, CHIL significantly expanded its operational capacity: Manufacturing infrastructure grew to two facilities, including an additional 6,000…

CHIL became one of the first five companies worldwide to manufacture COVID-19 antigen tests, reinforcing its pioneering position in rapid…

With the onset of the pandemic, CHIL rapidly initiated the in-house production and export of its first antibody tests. This…

In February 2018, CHIL participated in Medlab Middle East, Dubai. In November 2018, CHIL participated in MEDICA Messe Düsseldorf, Düsseldorf.

In response to growing operational needs, CHIL transitioned into a 1,000 m² manufacturing facility. This move marked a strategic shift…

In January 2016, CHIL participated in Arab Health, Dubai. In November 2016, CHIL participated in MEDICA Messe Düsseldorf, Düsseldorf.

CHIL EIA tests were used as reference tests in Saudi Arabia. This adoption established early confidence in the reliability and…

In January 2014, CHIL participated in Arab Health, Dubai. In November 2014, CHIL participated in MEDICA Messe Düsseldorf, Düsseldorf.

In January 2013, CHIL participated in Arab Health, Dubai. In November 2013, CHIL participated in MEDICA Messe Düsseldorf, Düsseldorf.

In January 2013, CHIL participated in Arab Health, Dubai. In November 2013, CHIL participated in MEDICA Messe Düsseldorf, Düsseldorf.